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nature of the symptoms, CART was discontinued; which led to
improvement of the symptoms. Reintroducing CART after 8 weeks
resulted in recurrence of the same symptoms, at which point
prednisone was added to the ongoing MAC and CART treatment.
After 4 weeks CD4 is 107, VL 957, and patient has tolerated CART
with no complications and Prednisone is being tapered.
Discussion: Currently there are no accepted criteria for diagnosis
of IRIS. The need to stop CART in cases of severe IRIS is controver-
sial. In some cases like ours, where temporary discontinuation of
CART may not be effective or appropriate, adding corticosteroids
to the regimen can help control the exaggerated inﬂammatory
response.
PP-149 Patient centered peer based program to improve
adherence to HIV therapy. The HATS-PC initiative
Adetunji Adejumo, Cynthia Lee*, Wafaar El-Sadr,
Sharon Mannheimer. Div. of Infectious Disease, Dept. of
Medicine, Harlem Hosp Ctr., Columbia University, New York, USA
Background: The success of HIV treatment depends on high
adherence rate (>95%) to antiretroviral therapy (ART). With
over one-third of patients reporting active substance use, we
estimated that over half may be non adherent or at risk of non
adherence.
Methods: HATS-PC program is a patient-centered, multidisci-
plinary adherence support team that includes peer worker, case
worker, HIV primary care providers and a program coordina-
tor/health educator. Peer workers are HIV-infected individuals
from the same community, adherent to ART, with good commu-
nication skills and commitment to helping others. Program peer
workers received a 6-week training focused on HIV/ART, and
counseling techniques. Adherence is measured by a 7-day self
report assessment, evaluation of laboratory data at baseline,
then quarterly and stage of behavioral change.
Results: 21 HIV-infected patients were enrolled in 2008, assigned
to 2 peer workers. 66% (n =14) female and 33% (n = 7) male, mean
age 43.2y (range 28-59). At program entry, majority 81% (n = 17)
had HIV RNA between 480 copies/ml and ≥100,000 copies/ml
(71% women, mean age 37, mean CD4 258 cells/uL).
The main reason for non-adherence was substance use (43%).
Other reasons were depression (23%), communication barrier
(14%) and medication side effect (9%).
62% (n = 13) graduated from the program having achieved a
target of >95% adherence for 6 months.
LESSONS LEARNED: Peer based adherence support can improve
adherence to treatment. Additionally, there is need for speciﬁc
interventions to address substance use in this population.
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Objective: To investigate the change of peripheral dendritic cell
(DC)subsets in individuals infected with HIV who were treated
with Ailing granule, a traditional Chinese drug.
Method: 17 cases who had not taken anti-viral medicines were
treated with AiLing granule for 9 months.11 cases were set as
normal control. The percentages of PDC and MDC were deter-
mined by ﬂow cytometry. At the same time, the ability of PDC to
produce IFN-α was also determined.
Results: The percentage of MDC in individuals treated with Ailing
granule for 3 or 9 months was signiﬁcantly higher than that before
the treatment, and returned to a normal level. The percentage
of PDC in individuals treated for 9 months was signiﬁcantly higher
than that before-treatment and also returned to a normal level.
The value of IFN-α in individuals treated for 9 months was el-
evated and had statistically signiﬁcant difference as compared
with that before treatment.
Conclusion: Ailing granule could increase to a certain extent the
percentage of MDC and PDC and elevate the ability of PDC to
produce IFN-α, thus raising immunity of the infected individuals.
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James Muthotho*. Health Promotion - King Baudouin Foundation
Kenya
Introduction: The herpes zoster infection is on the increase.
The antiviral drugs and analgesics infection are very expensive,
secondary bacteria infection is a problem,herpes acute pain and
post-herpetic neuralgia are a major cause of HIV/AIDS patient
morbidity. Health workers in Kenya have come with an ointment
made from plumeria alba plant, Chlorhexidine gluconate and
cetrimide for treating herpes zoster. This to eliminate acute neu-
ralgia, post herpetic neuralgia, kill the virus, prevent secondary
bacterial infection and control itching. To reduce these problems
herb extracts were tested for their efﬁcacy.
Method: Phytochemistry was done & HEP2 cells was usedto grow
virus. Extract was made in ﬁne powder form,diluted in petroleum
jelly 6mg plumeria alba extract in 100 g, chlorhexdine gluconate
0.001125 mg and cetrimide 0.01125 mg is added to prevent
secondary bacteria infection. Nontoxic extracts were applied on
herpes blisters. Neutralization of pain and inhibition of viruses
were monitored.
Results: Extract has polyphenolic compounds, and non-toxic car-
diac glycosides. This extract inhibits the growth of viruses when is
diluted up to 1:32. When it was applied on the patient’s blisters 3
times daily, the culture from vesical ﬂuid were negative within 3
days. The neurogia pain was eliminated within 10 minutes. while
those who were treated with antiviral drugs continued to have
post herpetic neuralgia. This ointment preparation, plumeria
alba has polyphenolics which kills the viruses and also eliminates
neuralgia during active infection and post herpetic neuralgia and
bacteria infection.
Observation: The patients treared with this drug d’nt get recur-
rent Herpes and post herpartic neuralgia
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Objective: Hepatitis C virus (HCV), hepatitis B virus (HBV) and
human immunodeﬁciency virus (HIV) are three most important
viral agents, responsible for transfusion transmitted infections
(TTIs). Study aim was to estimate the prevalence of HBV, HCV
and HIV among young blood donors in south Asian country, India.
Methods: Seroprevalence of HBsAg, anti-HCV and anti-HIV1/2
was studied among 13,671 young blood donors (mean age 18±9
yrs) from February 2007 to August 2008 at Blood Bank Depart-
ment, G.B. Pant Hospital, Tripura, India. Samples were screened
by using third generation ELISA Among total, 17.2% (n=2351)
were volunteers and rest were replacement donors. Standard-
ized questionnaire was designed to access social and clinical risk
factors, informed consent was taken from each participant.
Results: Among 13671, total seropositive rate was 2.71% (n=370),
